Clinical Perspectives

Genitourinary Oncology Advancement Update from ASCO 2024

Dr. Monica Chatwal, in the Genitourinary Oncology Department, shared some of the exciting treatments for genitourinary cancers at ASCO 2024.

Moffitt Researchers Investigating CAR T Therapy Feasibility in Metastatic Castration-resistant Prostate Cancer

Dr. Jingsong Zhang is leading a phase I trial of an infusion of autologous gamma delta T cells genetically engineered with a CAR T to target the...

Emerging Therapeutic Landscape in Genitourinary Oncology

The field of genitourinary (GU) oncology has witnessed a paradigm shift with the advent of pioneering therapies for prostate, bladder, kidney,...

Surgical Expertise Only at Moffitt

The surgical teams at Moffitt have unparalleled skills and are familiar with treating and studying even the rarest cancers.  

Insights on the Management of Glioma Patients and Treatment Innovations

The glioma landscape, particularly those with the H3 K27M mutation, presents unique challenges and opportunities for patient management and treatment...

How Community Collaboration Helps Optimize Cancer Care Outcomes

Moffitt’s highly specialized experts alongside our community to share insights into the latest innovations and best practices so that patients in the...

GI Surgical Oncology Team Stands at the Forefront of Treatment

The surgeons in the GI Surgical Oncology group are national leaders in surgical and cancer management.

Treating Benign Thyroid Nodules with Radiofrequency Ablation (RFA)

Radiofrequency ablation (RFA) employs a minimally invasive technique to treat benign thyroid nodules, attributing to a high satisfaction in patient...

Researchers Investigating TIL Therapy Feasibility in Head and Neck Squamous Cell Cancer

Dr. Kedar Kirtane is the principal investigator for a Phase IB clinical trial focusing on Squamous Cell Cancer Tumor-Infiltrating Lymphocytes (TIL).

How a CRC Enhances the Patient’s Journey at Moffitt

Clinical research coordinators at Moffitt are essential pillars in executing clinical trials.

FDA Approves CARVYKTI® and ABECMA for Early Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma

On April 5, 2024, the FDA revised the indications of both approved CAR T cell therapies for relapsed multiple myeloma to allow the use of these...

Advancements in Non-Muscle Invasive Bladder Cancer Treatment

The FDA has approved many alternative treatment methods for NMIBC, and several others are being investigated in clinical efficacy trials.

Pioneering Advances in Upper Extremity Oncologic Reconstruction and Endoprosthetic Reverse Shoulder Technology

Reverse shoulder technology is a new, promising solution that allows for improved shoulder function. At Moffitt, patients have access to a leading...

Advancements in Pancreatic Cancer Vaccines: A New Frontier in Immunotherapy Treatment

The landscape of pancreatic cancer treatment is evolving, driven by innovative approaches such as immunotherapy and pancreatic cancer vaccines.

FAQ: Revolutionizing Radiation Treatment with Proton Therapy

Proton therapy is an effective alternative to standard radiation treatment for patients who need to protect sensitive healthy tissue and organs.